Therapy for opioid dependence - An update;Therapie der opioidabhängigkeit - Ein update

Schweizer Archiv fur Neurologie und Psychiatrie

Volumn 161, Issue 1, 2010, Pages 5-13

  Vogel, Marc ^a   Petitjean, Sylvie ^a   Borgwardt, Stefan ^b   Wiesbeck, Gerhard A ^a   Walter, Marc ^a  

^a Universitäre Psychiatrische Kliniken   (Switzerland)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Buprenorphine; Heroin; Methadone; Opioid dependence; Opioid maintenance treatment; Psychosocial treatment

Indexed keywords

ALCOHOL; AMITRIPTYLINE; BENZODIAZEPINE; BUPRENORPHINE; BUPRENORPHINE PLUS NALOXONE; CARBAMAZEPINE; CLONIDINE; COCAINE; DIAMORPHINE; DIAZEPAM; DIHYDROCODEINE; DOXEPIN; IPRATROPIUM BROMIDE; LEVACETYLMETHADOL; LOFEXIDINE; LOPERAMIDE; MEBEVERINE; METHADONE; METOCLOPRAMIDE; MORPHINE; NALTREXIN; NALTREXONE; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; UNCLASSIFIED DRUG;

COGNITIVE THERAPY; COMORBIDITY; DEPRESSION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIARRHEA; DISEASE COURSE; HUMAN; MAINTENANCE THERAPY; MEDICAL SOCIETY; MENTAL DISEASE; OPIATE ADDICTION; PREVALENCE; PROGNOSIS; PSYCHOSOCIAL CARE; REVIEW; SLOW RELEASE FORMULATION;

EID: 77149159436     PISSN: 02587661     EISSN: None     Source Type: Journal    
DOI: 10.4414/sanp.2010.02125     Document Type: Review

References (94)

1. Ladewig D. Sucht und Suchtkrankheiten Ursachen, Symptome, Therapien. 3. Aufl. ed. München: Verlag C. H. Beck; 2002.
2. Möller H-J, Laux G, Deister A, Braun-Scharm H. Psychiatrie und Psychotherapie. 3. überarb. Aufl. ed. Stuttgart: Georg Thieme; 2005.
3. Leshner AI. Addiction is a brain disease, and it matters. Science. 1997; 278(5335):45-7.
4. Schweizerische Gesellschaft für Suchtmedizin (SSAM). Medizinische Empfehlungen für substitutionsgestützte Behandlungen (SGB) bei Opioidabhängigkeit. 2006.
5. Schmidt LG, Gastpar M, Falkai P, Gaebel W. Evidenzbasierte Suchtmedizin Behandlungsleitlinie substanzbezogene Störungen. Köln: Deutscher Ärzte-Verlag; 2006.
6. American Psychiatric Association (APA). Practice Guideline for the Treatment of Patients with Substance Use Disorders. Second Edition. ed. Washington, DC: American Psychiatric Association 2006.
7. NICE. Naltrexone for the management of opioid dependence. London: National Institute for Health and Clinical Excellence; 2007.
8. NICE. Methadone and buprenorphine for the management of opioid dependence. London: National Institute for Health and Clinical Excellence; 2007.
9. NICE. Drug Misuse: Opiate Detoxification. London: National Institute for Health and Clinical Excellence; 2007.
10. Department of Health (England), and the devolved administrations. Drug Misuse and Dependence: UK Guidelines on Clinical Management. London: Department of Health (England), the Scottish Government, Welsh Assembly Government and Northern Ireland Executive; 2007.
11. Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62(6):593-602.
12. McBride O, Teesson M, Slade T, Hasin D, Degenhardt L, Baillie A. Further evidence of differences in substance use and dependence between Australia and the United States. Drug Alcohol Depend. 2009;100(3): 258-64.
13. Bundesamt für Gesundheit (BAG). Die Heroingestützte Behandlung mit Diacetylmorphin (HeGeBe) im Jahre 2007. Bern; 2009.
14. Schweiz Bundesanwaltschaft Zentralpolizeibüro, Schweiz Bundesamt für Polizeiwesen Zentralstelle Rauschgift. Schweizerische Betäubungsmittelstatistik. Bern: Schweizerische Bundesanwaltschaft Zentralpolizeibüro; 2005.
15. Bundesamt für Gesundheit (BAG). Nationale Methadonstatistik 2004. Bern; 2005.
16. Nordt C, Stohler R. Incidence of heroin use in Zurich, Switzerland: a treatment case register analysis. Lancet. 2006;367(9525):1830-4.
17. Seidenberg A, Honegger U. Methadon, Heroin und andere Opioide medizinisches Manual für die ambulante opioidgestützte Behandlung. Bern: Verlag Hans Huber; 1998.
18. Sass H, American Psychiatric Association. Diagnostisches und statistisches Manual psychischer Störungen Textrevision - DSM-IV-TR, übersetzt nach der Textrevision der 4. Auflage des "Diagnostic and statistical manual of mental disorders" der American Psychiatric Association. Göttingen: Hogrefe; 2003.
19. Dilling H, Mombour W, Schmidt MH, World Health Organization. Internationale Klassifikation psychischer Störungen ICD-10 Kapitel V (F) klinischdiagnostische Leitlinien. Bern 〈etc.〉: Huber; 1991.
20. Uchtenhagen A, Zieglgänsberger W. Suchtmedizin Konzepte, Strategien und therapeutisches Management. München: Urban & Fischer; 2000.
21. McKay JR, Alterman AI, Mulvaney FD, Koppenhaver JM. Predicting proximal factors in cocaine relapse and near miss episodes: clinical and theoretical implications. Drug Alcohol Depend. 1999;56(1):67-78.
22. Le Moal M, Koob GF. Drug addiction: pathways to the disease and pathophysiological perspectives. Eur Neuropsychopharmacol. 2007; 17(6-7):377-93.
23. Walter M, Wiesbeck GA, Bloch N, Aeschbach S, Olbrich HM, Seifritz E, et al. Psychobiological responses to drug cues before and after methadone intake in heroin-dependent patients: a pilot study. Eur Neuropsychopharmacol. 2008;18(5):390-3.
24. Williams TM, Daglish MR, Lingford-Hughes A, Taylor LG, Hammers A, Brooks DJ, et al. Brain opioid receptor binding in early abstinence from opioid dependence: positron emission tomography study. Br J Psychiatry. 2007;191:63-9.
25. Rocha L, Tatsukawa K, Chugani HT, Engel J, Jr. Benzodiazepine receptor binding following chronic treatment with naloxone, morphine and met-enkephalin in normal rats. Brain Res. 1993;612(1-2):247-52.
26. Moggi F, Donati R. Psychische Störungen und Sucht: Doppeldiagnosen. Göttingen: Hogrefe Verl. für Psychologie; 2004.
27. Morgenstern J, Langenbucher J, Labouvie E, Miller KJ. The comorbidity of alcoholism and personality disorders in a clinical population: prevalence rates and relation to alcohol typology variables. J Abnorm Psychol. 1997;106(1):74-84.
28. Verheul R. Co-morbidity of personality disorders in individuals with substance use disorders. Eur Psychiatry. 2001;16(5):274-82.
29. Goldstein RB, Compton WM, Pulay AJ, Ruan WJ, Pickering RP, Stinson FS, et al. Antisocial behavioral syndromes and DSM-IV drug use disorders in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Drug Alcohol Depend. 2007;90(2-3): 145-58.
30. Walter M, Gunderson JG, Zanarini MC, Sanislow CA, Grilo CM, McGlashan TH, et al. New onsets of substance use disorders in borderline personality disorder over 7 years of follow-ups: findings from the Collaborative Longitudinal Personality Disorders Study. Addiction. 2009;104(1):97-103.
31. Grella CE, Karno MP, Warda US, Niv N, Moore AA. Gender and comorbidity among individuals with opioid use disorders in the NESARC study. Addict Behav. 2009 Jan 30.
32. Brooner RK, King VL, Kidorf M, Schmidt CW Jr, Bigelow GE. Psychiatric and substance use comorbidity among treatment-seeking opioid abusers. Arch Gen Psychiatry. 1997;54(1):71-80.
33. Galen LW, Brower KJ, Gillespie BW, Zucker RA. Sociopathy, gender, and treatment outcome among outpatient substance abusers. Drug Alcohol Depend. 2000;61(1):23-33.
34. Basu D, Ball SA, Feinn R, Gelernter J, Kranzler HR. Typologies of drug dependence: comparative validity of a multivariate and four univariate models. Drug Alcohol Depend. 2004;73(3):289-300.
35. Swann AC, Bjork JM, Moeller FG, Dougherty DM. Two models of impulsivity: relationship to personality traits and psychopathology. Biol Psychiatry. 2002;51(12):988-94.
36. Forman SD, Dougherty GG, Casey BJ, Siegle GJ, Braver TS, Barch DM, et al. Opiate addicts lack error-dependent activation of rostral anterior cingulate. Biol Psychiatry. 2004;55(5):531-7.
37. Lee TM, Zhou WH, Luo XJ, Yuen KS, Ruan XZ, Weng XC. Neural activity associated with cognitive regulation in heroin users: A fMRI study. Neurosci Lett. 2005;382(3):211-6.
38. Ladewig D. Mehrfachabhängigkeiten. In: Uchtenhagen A, Zieglgänsberger W, editors. Suchtmedizin. München: Urban & Fischer; 2000. p. 269-71.
39. Scheurich A, Muller MJ, Wetzel H, Anghelescu I, Klawe C, Ruppe A, et al. Reliability and validity of the German version of the European Addiction Severity Index (EuropASI). J Stud Alcohol. 2000;61(6):916-9.
40. Wittchen H-U, Zaudig M, Fydrich T. SKID strukturiertes klinisches Interview für DSM-IV Achse I und II. Göttingen 〈etc.〉: Hogrefe; 1997.
41. Jasinski DR, Johnson RE, Kocher TR. Clonidine in morphine withdrawal. Differential effects on signs and symptoms. Arch Gen Psychiatry. 1985; 42(11):1063-6.
42. San L, Fernandez T, Cami J, Gossop M. Efficacy of methadone versus methadone and guanfacine in the detoxification of heroin-addicted patients. J Subst Abuse Treat. 1994;11(5):463-9.
43. Eap CB, Buclin T, Baumann P. Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence. Clin Pharmacokinet. 2002;41(14):1153-93.
44. Prosser J, Cohen LJ, Steinfeld M, Eisenberg D, London ED, Galynker, II. Neuropsychological functioning in opiate-dependent subjects receiving and following methadone maintenance treatment. Drug Alcohol Depend. 2006;84(3):240-7.
45. Soyka M, Lieb M, Kagerer S, Zingg C, Koller G, Lehnert P, et al. Cognitive functioning during methadone and buprenorphine treatment: results of a randomized clinical trial. J Clin Psychopharmacol. 2008;28(6):699-703.
46. Verdejo A, Toribio I, Orozco C, Puente KL, Perez-Garcia M. Neuropsychological functioning in methadone maintenance patients versus abstinent heroin abusers. Drug Alcohol Depend. 2005;78(3):283-8.
47. Gruber SA, Tzilos GK, Silveri MM, Pollack M, Renshaw PF, Kaufman MJ, et al. Methadone maintenance improves cognitive performance after two months of treatment. Exp Clin Psychopharmacol. 2006;14(2):157-64.
48. O'Connor PG, Carroll KM, Shi JM, Schottenfeld RS, Kosten TR, Rounsaville BJ. Three methods of opioid detoxification in a primary care setting. A randomized trial. Ann Intern Med. 1997;127(7):526-30.
49. Janiri L, Mannelli P, Persico AM, Serretti A, Tempesta E. Opiate detoxification of methadone maintenance patients using lefetamine, clonidine and buprenorphine. Drug Alcohol Depend. 1994;36(2):139-45.
50. Nigam AK, Ray R, Tripathi BM. Buprenorphine in opiate withdrawal: a comparison with clonidine. J Subst Abuse Treat. 1993;10(4):391-4.
51. Walsh SL, Preston KL, Stitzer ML, Cone EJ, Bigelow GE. Clinical pharmacology of buprenorphine: ceiling effects at high doses. Clin Pharmacol Ther. 1994;55(5):569-80.
52. Charney DS, Sternberg DE, Kleber HD, Heninger GR, Redmond DE, Jr. The clinical use of clonidine in abrupt withdrawal from methadone. Effects on blood pressure and specific signs and symptoms. Arch Gen Psychiatry. 1981;38(11):1273-7.
53. Kleber HD, Riordan CE, Rounsaville B, Kosten T, Charney D, Gaspari J, et al. Clonidine in outpatient detoxification from methadone maintenance. Arch Gen Psychiatry. 1985;42(4):391-4.
54. Cami J, de Torres S, San L, Sole A, Guerra D, Ugena B. Efficacy of clonidine and of methadone in the rapid detoxification of patients dependent on heroin. Clin Pharmacol Ther. 1985;38(3):336-41.
55. Preston KL, Bigelow GE, Liebson IA. Self-administration of clonidine, oxazepam, and hydromorphone by patients undergoing methadone detoxification. Clin Pharmacol Ther. 1985;38(2):219-27.
56. Ghodse H, Myles J, Smith SE. Clonidine is not a useful adjunct to methadone gradual detoxification in opioid addiction. Br J Psychiatry. 1994;165(3):370-4.
57. Maddux JF, Desmond DP. Methadone maintenance and recovery from opioid dependence. Am J Drug Alcohol Abuse. 1992;18(1):63-74.
58. Faggiano F, Vigna-Taglianti F, Versino E, Lemma P. Methadone maintenance at different dosages for opioid dependence. Cochrane Database Syst Rev. 2003(3):CD002208.
59. Mattick RP, Kimber J, Breen C, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2008(2):CD002207.
60. Petitjean S, Stohler R, Deglon JJ, Livoti S, Waldvogel D, Uehlinger C, et al. Double-blind randomized trial of buprenorphine and methadone in opiate dependence. Drug Alcohol Depend. 2001;62(1):97-104.
61. Penning R, Fromm E, Betz P, Kauert G, Drasch G, von Meyer L. Drug death autopsies at the Munich Institute of Forensic Medicine (1981-1992). Forensic Sci Int. 1993;62(1-2):135-9.
62. Eder H, Jagsch R, Kraigher D, Primorac A, Ebner N, Fischer G. Comparative study of the effectiveness of slow-release morphine and methadone for opioid maintenance therapy. Addiction. 2005;100(8):1101-9.
63. Verthein U, Bonorden-Kleij K, Degkwitz P, Dilg C, Kohler WK, Passie T, et al. Long-term effects of heroin-assisted treatment in Germany. Addiction. 2008;103(6):960-6; discussion 7-8.
64. Zukin RS, Sugarman JR, Fitz-Syage ML, Gardner EL, Zukin SR, Gintzler AR. Naltrexone-induced opiate receptor super-sensitivity. Brain Res. 1982; 245(2):285-92.
65. Waal H, Kornør H. Abstinence-oriented therapies for opiate addicts. Curr Opin Psychiatry. 2004;17(3):169-74.
66. Alho H, Sinclair D, Vuori E, Holopainen A. Abuse liability of buprenorphinenaloxone tablets in untreated IV drug users. Drug Alcohol Depend. 2007; 88(1):75-8.
67. Mayet S, Farrell M, Ferri M, Amato L, Davoli M. Psychosocial treatment for opiate abuse and dependence. Cochrane Database Syst Rev. 2004(4):CD004330.
68. Amato L, Minozzi S, Davoli M, Vecchi S, Ferri MM, Mayet S. Psychosocial and pharmacological treatments versus pharmacological treatments for opioid detoxification. Cochrane Database Syst Rev. 2008(3):CD005031.
69. Amato L, Minozzi S, Davoli M, Vecchi S, Ferri M, Mayet S. Psychosocial combined with agonist maintenance treatments versus agonist maintenance treatments alone for treatment of opioid dependence. Cochrane Database of Systematic Reviews 2008, Issue 4. Art. No.: CD004147.
70. Woody GE, McLellan AT, Luborsky L, O'Brien CP. Psychotherapy in community methadone programs: a validation study. Am J Psychiatry. 1995;152(9):1302-8.
71. Stanton MD, Shadish WR. Outcome, attrition, and family-couples treatment for drug abuse: a meta-analysis and review of the controlled, comparative studies. Psychol Bull. 1997;122(2):170-91.
72. Irvin JE, Bowers CA, Dunn ME, Wang MC. Efficacy of relapse prevention: a meta-analytic review. J Consult Clin Psychol. 1999;67(4):563-70.
73. Linehan MM, Dimeff LA, Reynolds SK, Comtois KA, Welch SS, Heagerty P, et al. Dialectical behavior therapy versus comprehensive validation therapy plus 12-step for the treatment of opioid dependent women meeting criteria for borderline personality disorder. Drug Alcohol Depend. 2002; 67(1):13-26.
74. Ball SA. Comparing individual therapies for personality disordered opioid dependent patients. J Pers Disord. 2007;21(3):305-21.
75. Gregory RJ, Remen AL. A manual-based psychodynamic therapy for treatment-resistant borderline personality disorder. Psychotherapy: Theory, Research, Practice, Training Mar 2008;45(1):15-27.
76. Miller WR, Rollnick S. Motivational interviewing: preparing people for change. 2nd ed. New York: Guilford Press; 2002.
77. Rogers CR. Client-centered therapy: [S.l.]: Houghton Mifflin, 1951 (1973).
78. Carroll KM, Onken LS. Behavioral therapies for drug abuse. Am J Psychiatry. 2005;162(8):1452-60.
79. Carroll KM. Recent advances in the psychotherapy of addictive disorders. Curr Psychiatry Rep. 2005;7(5):329-36.
80. Secades-Villa R, Fernande-Hermida JR, Arnaez-Montaraz C. Motivational interviewing and treatment retention among drug user patients: a pilot study. Subst Use Misuse. 2004;39(9):1369-78.
81. Saunders B, Wilkinson C, Phillips M. The impact of a brief motivational intervention with opiate users attending a methadone programme. Addiction. 1995;90(3):415-24.
82. Carroll KM, Ball SA, Nich C, O'Connor PG, Eagan DA, Frankforter TL, et al. Targeting behavioral therapies to enhance naltrexone treatment of opioid dependence: efficacy of contingency management and significant other involvement. Arch Gen Psychiatry. 2001;58(8):755-61.
83. Dutra L, Stathopoulou G, Basden SL, Leyro TM, Powers MB, Otto MW. A meta-analytic review of psychosocial interventions for substance use disorders. Am J Psychiatry. 2008;165(2):179-87.
84. Stitzer ML, Iguchi MY, Felch LJ. Contingent take-home incentive: effects on drug use of methadone maintenance patients. J Consult Clin Psychol. 1992;60(6):927-34.
85. Petry NM, Martin B, Simcic F Jr. Prize reinforcement contingency management for cocaine dependence: integration with group therapy in a methadone clinic. J Consult Clin Psychol. 2005;73(2):354-9.
86. Roozen HG, Boulogne JJ, van Tulder MW, van den Brink W, De Jong CA, Kerkhof AJ. A systematic review of the effectiveness of the community reinforcement approach in alcohol, cocaine and opioid addiction. Drug Alcohol Depend. 2004;74(1):1-13.
87. Marlatt GA, Gordon JR. Relapse prevention: maintenance strategies in the treatment of addictive behaviors. New York: Guilford Press; 1985.
88. Woody GE. Research findings on psychotherapy of addictive disorders. Am J Addict. 2003;12 (Suppl 2):S19-26.
89. O'Neill K, Baker A, Cooke M, Collins E, Heather N, Wodak A. Evaluation of a cognitive-behavioural intervention for pregnant injecting drug users at risk of HIV infection. Addiction. 1996;91(8):1115-25.
90. Borgwardt SJ, Allen P, Bhattacharyya S, Fusar-Poli P, Crippa JA, Seal ML, et al. Neural basis of Delta-9-tetrahydrocannabinol and cannabidiol: effects during response inhibition. Biol Psychiatry. 2008;64(11):966-73.
91. Fusar-Poli P, Crippa JA, Bhattacharyya S, Borgwardt SJ, Allen P, Martin-Santos R, et al. Distinct effects of {delta}9-tetrahydrocannabinol and cannabidiol on neural activation during emotional processing. Arch Gen Psychiatry. 2009;66(1):95-105.
92. Levran O, Londono D, O'Hara K, Nielsen DA, Peles E, Rotrosen J, et al. Genetic susceptibility to heroin addiction: a candidate gene association study. Genes Brain Behav. 2008;7(7):720-9.
93. Stoermer R, Drewe J, Dursteler-Mac Farland KM, Hock C, Mueller-Spahn F, Ladewig D, et al. Safety of injectable opioid maintenance treatment for heroin dependence. Biol Psychiatry. 2003;54(8):854-61.
94. Langleben DD, Ruparel K, Elman I, Busch-Winokur S, Pratiwadi R, Loughead J, et al. Acute effect of methadone maintenance dose on brain FMRI response to heroin-related cues. Am J Psychiatry. 2008;165(3):390-4.